Using this technology platform, Abzyme develops various types of antibodies including, but not limited to camelid and human single domain antibodies, human ScFv and full human IgG.
Filing this application is very important milestone for Abzyme Therapeutics.
To make an abzyme that specifically cleaves phenylacetate, the researchers obtained antibodies that bind to another longer-lived molecule that is similar in form to phenylacetate's fleeting transition-state.
Since all antibodies are structurally similar, the scientists expect that their success at getting the phenylacetate-cleaving abzyme to work in a reverse micelle will extend to other abzymes.
Now a team of six scientists has coaxed abzymes into doing something new -- work in a greasy, organic environment that normally would deactivate them.
A reactant chemical, dissolved in the isooctane, penetrates into the reverse micelles, where the abzymes catalyze reaction, in this case cleaving the phenylacetate molecules.